journal
MENU ▼
Read by QxMD icon Read
search

Chinese Clinical Oncology

journal
https://www.readbyqxmd.com/read/30509081/douglas-g-mcneel-stay-current-reading-research-literature-there-is-no-substitute-for-hard-work
#1
Brad Li
No abstract text is available yet for this article.
December 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30509080/pathological-response-of-ovarian-cancer-to-neoadjuvant-chemotherapy
#2
Alexandr O Ivantsov
There is only a few of studies devoted to evaluation of pathologic response of ovarian cancer (OC) to neoadjuvant chemotherapy (NACT). Pathologic complete responses (pCR), which are characterized by the lack of viable tumor cells in surgical specimens, are rarely observed in ovarian carcinomas. Multiple reports demonstrate that pCR is associated with evidently improved disease outcomes. Recommendations of the International Collaboration on Cancer Reporting suggest to use recently developed Chemotherapy Response Scoring (CRS) system, which is based on the pathological analysis of surgically removed omental masses...
December 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30509079/neoadjuvant-chemotherapy-in-advanced-ovarian-cancer-optimal-patient-selection-and-response-evaluation
#3
Jae Hyun Cho, Seik Kim, Yong Sang Song
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancy and is the seventh most common cancer among women worldwide. The primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT) is a standard treatment of advanced EOC. However, there are still several limitations, such as high recurrence rate and subsequent chemoresistance. To date, many studies have reported that neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) shows non-inferior survival outcome and is associated with less postoperative morbidity compared with PDS...
December 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30509078/principles-of-clinical-management-of-ovarian-cancer
#4
Tatiana V Gorodnova, Anna P Sokolenko, Ekatherina Kuligina, Igor V Berlev, Evgeny N Imyanitov
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is usually diagnosed at advanced stages. Cytoreductive surgery is a backbone of EOC treatment. Wherever possible, EOC patients are subjected to primary debulking surgery (PDS) with the aim to remove all visible tumor lumps. Some patients cannot undergo PDS due to extensive disease spread and/or high risk of perioperative morbidity, therefore they are subjected to neoadjuvant chemotherapy (NACT) before the surgery...
December 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30509077/neoadjuvant-therapy-theoretical-biological-and-medical-consideration
#5
Evgeny N Imyanitov, Grigoriy A Yanus
Neoadjuvant therapy (NAT) is widely utilized in the routine management of cancer patients and various clinical trials for the treatment of breast, ovarian, rectal, esophageal, head and neck, lung, prostate and many other cancer types. There is a number of potential benefits of applying systemic treatment before the operation. NAT may significantly reduce the tumor burden thus allowing less traumatic surgery. NAT is often considered as personalized in vivo drug sensitivity test, as it allows rapid evaluation of tumor response to a given therapy and consequent adjustment of further treatment planning...
December 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30509076/neoadjuvant-therapy-for-ovarian-cancer
#6
Evgeny N Imyanitov
No abstract text is available yet for this article.
December 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30395718/management-of-fibrolamellar-hepatocellular-carcinoma
#7
Ikram A Chaudhari, Krunal Khobragade, Manish Bhandare, Shailesh V Shrikhande
Fibrolamellar hepatocellular carcinoma (FLHCC) is a primary liver tumor. It is a pathologically distinct variety of hepatocellular carcinoma (HCC). The term 'fibrolamellar' is derived from the presence of thick fibrous collagen bands surrounding the tumor cells. It is a relatively rare tumor of unknown biology. It has a distinctive predilection for adolescents and young adults with no underlying liver disease or cirrhosis. FLHCC patients have higher incidence of lymph node involvement than conventional HCC patients probably owing to larger median tumor size at presentation...
October 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30395717/systemic-therapy-for-hepatocellular-carcinoma-beyond-sorafenib
#8
Patrick Boland, Jennifer Wu
Hepatocellular carcinoma (HCC) remains the second leading cause of cancer mortality worldwide and the fifth leading cause of cancer-related deaths in the United States. In 2007, sorafenib became the first Food and Drug Administration (FDA) approved first line systemic treatment for HCC, however, it confers only modest benefit in median overall survival (mOS) and comes with significant side effects. This review article will explore systemic treatments for incurable HCC beyond sorafenib. It will pay particular emphasis to various kinase inhibitors, immunotherapies, and new data on combination therapies...
October 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30395716/hepatocellular-carcinoma-surgical-therapy-perspectives-on-the-current-limits-to-resection
#9
Akhil Chawla, Cristina Ferrone
Hepatocellular carcinoma (HCC) patients often present with late stage disease, which removes surgical resection from the therapeutic treatment options. Only patients with very early disease are recommended for a potentially curative surgical resection. These guidelines have been broadly challenged due to the lack of evidence supporting the use of local therapies over surgery for resectable disease. This review highlights the role of surgical resection for HCC by disease stage, and reports data that supports treatment outside of the accepted Barcelona Clinic Liver Cancer (BCLC) treatment algorithm...
October 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30395715/current-status-and-evolving-treatment-for-primary-liver-cancers
#10
Andrew X Zhu, Thomas A Aloia
No abstract text is available yet for this article.
October 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30180753/role-of-interventional-radiology-in-the-management-of-hepatocellular-carcinoma-current-status
#11
Daniel J Holzwanger, David C Madoff
The treatment of patients with hepatocellular carcinoma requires a careful balance of adequate oncologic control and the preservation of both liver function and performance status. Over the last few decades, the emerging field of interventional oncology has introduced a variety of minimally invasive, safe and effective therapies, expanding the armament of available treatment options. The Barcelona Clinic Liver Cancer staging system is the most widely adopted treatment classification which aims to match patients with the therapies that will yield the best outcomes based on these factors...
October 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30180752/intrahepatic-cholangiocarcinoma-surgery-the-impact-of-lymphadenectomy
#12
Javier C Lendoire, Luis Gil, Oscar Imventarza
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignant tumor and its incidence is increasing over the world. At present times, radical liver resection is still the most effective treatment for ICC patients to achieve long term survival. Pathological lymph node metastases (LMN), found in 15% to 45% of the patients, have been recognized as an extremely poor prognostic risk factor, even if curative resection is performed. So, considering this issue, it acquires relevance to determine the validity of surgical resection for LNM cases that are diagnosed in the preoperative setting, or whether a routine lymphadenectomy should be performed systematically in all hepatectomies for ICC...
October 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30180751/intrahepatic-cholangiocarcinoma-the-ajcc-uicc-8th-edition-updates
#13
Andrew J Lee, Yun Shin Chun
Intrahepatic cholangiocarcinoma accounts for 5% to 30% of all primary liver cancers, and its incidence has increased in the last 3 decades. Surgical resection remains the only potentially curative treatment but is associated with high tumor recurrence rates. The 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual introduced a new staging system for intrahepatic cholangiocarcinoma, which was previously staged the same as hepatocellular carcinoma. The recently published 8th edition has subdivided the T1 category to T1a and T1b based on a size cutoff of 5 cm, removed periductal invasion from the T4 category, and downstaged T4 tumors and regional lymph node metastasis from stage IV to IIIB...
October 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30173536/soft-tissue-sarcoma-in-asia
#14
Eileen Poon, Richard Quek
Sarcoma is an uncommon and heterogeneous group of malignancies linked by their mesenchymal origin. They are rare and account for 1% of adult cancers, and 10-20% of adolescent and young adult (AYA) cancers. While there is good published literature on the incidence and distribution of sarcoma subtypes in the western populations, there is a paucity of data from Asia, particularly on the epidemiology, treatment and outcomes of STS in Asia. Formalized prospective national registries in soft tissue sarcoma (STS) are lacking and little is known about how sarcomas are treated and managed throughout the Asia-Pacific region...
August 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30173535/post-operative-surveillance-in-soft-tissue-sarcoma-using-tumor-specific-recurrence-patterns-to-direct-approach
#15
Mohammad Yahya Zaidi, Kenneth Cardona
Significant challenges exist in creating surveillance recommendations for soft tissue sarcomas (STS) given the vast heterogeneity of recurrence patterns between histologic subtypes. Using the most recent evidence on the natural history of STS, this review will propose surveillance strategies based on tumor location and histologic subtype.
August 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30173534/ny-eso-1-a-promising-cancer-testis-antigen-for-sarcoma-immunotherapy-and-diagnosis
#16
Stephen M Smith, O Hans Iwenofu
Sarcomas are heterogenous malignant mesenchymal neoplasms. These are often notoriously difficult to treat particularly in the metastatic setting. There is therefore an urgent need for development of better and more efficacious targeted therapies. Cancer testis antigens (CTAs) are a family of proteins in which aberrant gene-activation and subsequent high level mRNA expression, are restricted to testicular germ cells and are seen in certain malignancies. Importantly, the restriction of this class of antigens to testicular germ cells and malignancies and not somatic tissue, makes them an excellent choice for targeted immunotherapy...
August 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30173533/next-frontiers-in-systemic-therapy-for-soft-tissue-sarcoma
#17
Cheuh-Chuan Yen, Tom Wei-Wu Chen
Soft tissue sarcoma (STS) is a heterogeneous disease with more than 50 subtypes. Once the disease reached locally advanced or metastatic status, the standard treatment remains to be chemotherapy. Current understanding of the underlying molecular and genomic mechanisms of different histology subtypes have led to encouraging development of new drugs in treating STS. Besides molecular targeted therapy, immunotherapy have also shown promising advancement in solid tumor treatments. This review will be in two parts...
August 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30173532/advances-of-systemic-treatment-for-adult-soft-tissue-sarcoma
#18
Wenshuai Liu, Quan Jiang, Yuhong Zhou
Soft-tissue sarcoma (STS) is a group of rare but highly heterogeneous neoplasms. Systemic treatment with cytotoxic chemotherapy and targeted agents is one of the main therapeutic modalities in patients with unresectable or metastatic disease, while adjuvant and neoadjuvant chemotherapy for adult-type sarcomas remain controversial. Although an anthracycline (doxorubicin) and ifosfamide remain the cornerstone for chemotherapy, advances have been made recently to exceed its limited efficacy, other agents such as trabectedin, eribulin have been approved...
August 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30173531/decision-making-for-palliative-versus-curative-intent-treatment-of-retroperitoneal-sarcoma-rps
#19
Deanna Ng, Carol J Swallow
Curative treatment of RPS is predicated on complete macroscopic resection, but this is not appropriate in all cases, for a variety of tumour-, patient- and/or treatment-related reasons. Here we review the available literature to glean data that can guide patient selection for major extirpative surgery with its attendant risks or for palliative-intent management that emphasizes quality of life.
August 2018: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/30173530/surgical-management-of-retroperitoneal-sarcoma-and-opportunities-for-global-collaboration
#20
Jennifer Wang, Valerie P Grignol, Alessandro Gronchi, Cheng-Hua Luo, Raphael E Pollock, William W Tseng
Retroperitoneal sarcomas (RPS) are rare cancers that often reach massive size before detection. The mainstay of treatment for RPS is surgical resection, and complete resection is the only chance for potential cure. The management of RPS can be challenging and in individual cases, radiation and systemic therapy may be beneficial in both primary and recurrent disease. Further research through multi-institutional collaboration, ideally on a global level, is needed to better understand RPS and optimize management of this disease...
August 2018: Chinese Clinical Oncology
journal
journal
47887
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"